Key Highlights

● Hemab Therapeutics priced an upsized IPO at $18 per share on April 30, 2026, raising about $346.7 million in total proceeds, and its stock jumped almost 89% on debut.

● Parabilis Medicines, the former FogPharma, raised roughly $670 million in a June 9, 2026 IPO described as a record for a biotech offering, funding its Helicons stabilized-peptide platform.

● Eikon Therapeutics, led by former Merck research chief Roger Perlmutter, raised about $381 million in a February 4, 2026 IPO to fund its super-resolution live-cell imaging drug-discovery platform.

● Akoustis Technologies filed for Chapter 11 Bankruptcy in December 2024 after a roughly $59 million Qorvo Patent judgment, was Delisted from Nasdaq, and now trades over the counter as AKTSQ following an asset sale to a SpaceX subsidiary.

A cluster of 2026 Nasdaq newcomers shows how much fresh Capital is flowing back into life sciences, and, in one telling case, how brutally the market punishes a company that runs out of road.

Five Tickers, Four Stories About the Same Comeback

Four of the five tickers in this basket point at the most striking market story of 2026: the reopening of the biotech and health-technology financing window on the Nasdaq. Eikon Therapeutics, Hemab Therapeutics and Parabilis Medicines all completed sizeable initial public offerings this year, while Conexeu Sciences arrived on the smaller Nasdaq Capital Market with a regenerative-tissue pitch.

The fifth, Akoustis Technologies, does not belong to the sector at all. It is a radio-frequency semiconductor company that filed for bankruptcy and was pushed off the exchange. Grouping it with the others is instructive precisely because it is the counter-example: a reminder that a Nasdaq listing guarantees nothing.

A Biotech IPO Window That Actually Opened

For most of 2023 and 2024, the biotech IPO market was effectively shut. What makes 2026 notable, on the record, is that several life-sciences companies priced deals investors were willing to pay up for.

Eikon Therapeutics raised roughly $381 million in a February listing. Hemab Therapeutics priced an upsized offering at the top of its range at $18 in late April, and its stock closed its first session near $34. Parabilis Medicines then set what was described as a record for a biotech IPO, raising about $670 million in June. Three deals, three enthusiastic debuts, all on the Nasdaq Global Select tier.

That is the factual backdrop. The analysis is more nuanced. Strong first-day pops tell you about Demand at the offering, not about durable value, and none of these companies sells a product yet. Each is spending heavily against clinical timelines that stretch years out. The 2026 window rewarded platform stories and rare-disease franchises with credible data; it did not repeal the biology risk underneath them.

Health technology, meanwhile, is a broader church than drug developers. Conexeu Sciences is a device-and-materials company, not a therapeutics house, and its path to market runs through the FDA's 510(k) clearance route rather than through Phase 3 efficacy trials. The distinction matters for anyone lumping biotech and health tech into one bucket.

Hemab Therapeutics (NASDAQ:COAG): A Rare-Bleeding-Disorder Bet Wearing Its Ticker on Its Sleeve

Hemab Therapeutics Holdings chose a ticker that spells out its focus, coagulation. The Cambridge, Massachusetts company is developing subcutaneous treatments for rare blood-clotting disorders.

On the facts, Hemab priced an upsized IPO at $18 per share on 30 April 2026, selling roughly 16.75 million shares for about $301.5 million in base gross proceeds; the company's closing release put total proceeds near $346.7 million once the over-allotment was counted. Goldman Sachs, Jefferies and Evercore ISI led the deal, and the stock jumped almost 89% on debut. Its lead asset, sutacimig (HMB-001), completed Phase 2 and is advancing toward Phase 3 in Glanzmann thrombasthenia, with a Phase 2 in Factor VII deficiency; HMB-002 is in Phase 1/2 for von Willebrand disease. Hemab reported a net loss of about $63.9 million for 2025 on no revenue.

Rare-disease franchises can command premium pricing and loyal patient populations, which is part of the appeal. Everything still depends on Phase 3 readouts that have not happened. Watch for pivotal-trial timing and cash runway disclosures.

Parabilis Medicines (NASDAQ:PBLS): The Record-Setting Undruggable Story

Parabilis Medicines is the former FogPharma, rebranded for its public debut. The company's platform, called Helicons, uses stabilized helical peptides intended to bind and modulate protein targets that conventional small molecules and antibodies struggle to reach.

On the record, Parabilis priced its IPO above range at $20 per share on 9 June 2026, offering 33.5 million shares and raising roughly $670 million, described as a record biotech IPO. Leerink Partners and BofA Securities led the offering. Shares opened around $33.35 and closed their first day near $31.60. The company's lead program, zolucatetide, targets desmoid tumors, with a Phase 3 study planned for the first half of 2027. Parabilis reported a net loss of roughly $152.9 million for the twelve months ended 31 March 2026.

The picture is a mix of ambition and caution. A near-$670 million raise buys years of runway and signals deep institutional conviction in the undruggable targets thesis. But the size of the raise also sets a high bar. The 2027 Phase 3 initiation is the event that converts platform narrative into hard clinical proof, or exposes the gap.

Eikon Therapeutics (NASDAQ:EIKN): Perlmutter's Imaging Platform Goes Public

Eikon Therapeutics carries an unusual pedigree. It is led by chief executive Roger Perlmutter, the former head of research at Merck, alongside co-founder Roy Baynes, another Merck clinical-development veteran.

Factually, Eikon raised about $381 million in an IPO that priced at $18 per share on 4 February 2026, selling more than 21 million shares on the Nasdaq. The company was built around super-resolution, live-cell microscopy meant to track how proteins move inside cells and speed drug discovery. Its most advanced program, EIK-1001, is a TLR7/8 agonist in Phase 2/3 testing in melanoma with a mid-stage study in non-small-cell lung cancer; a pair of PARP inhibitors sits in Phase 1, and a WRN helicase inhibitor is in development for MSI-high tumors. Reporting cites more than a dozen candidates across oncology and neurology.

Eikon is a rare thing: a platform company with both a marquee management team and a late-stage clinical asset. The melanoma readout is the swing factor. A strong result validates both the drug and the discovery engine; a miss reprices the whole story.

Conexeu Sciences (NASDAQ:CNXU): Regenerative Tissue on the Small-Cap Tier

Conexeu Sciences is the health-technology outlier here, a preclinical regenerative-medicine and medical-device company rather than a drug developer. Its platform, branded CXU, is a bioregenerative extracellular matrix.

On the record, Conexeu commenced trading on the Nasdaq Capital Market on 21 May 2026 under its current ticker; the debut was characterized as a direct listing. Company materials describe roughly 25.3 million shares outstanding, and around 35.2 million fully diluted, at listing. Its lead concepts include Ten Minute Tissue, an injectable matrix that gels at body temperature, and a 3D-bioprinted regenerative breast matrix called B.R.E.A.S.T. Target uses span wound care, periodontal health, body contouring and veterinary medicine. The company has said it plans a 510(k) submission for an initial wound-care indication in early 2027.

This is the highest-caution name in the group. A preclinical micro-cap on the Capital Market tier, arriving via a direct listing rather than an underwritten raise, sits at the highest-risk end of this group. Watch whether that 2027 regulatory submission actually lands on schedule, and watch Liquidity and financing needs closely.

Akoustis Technologies (NASDAQ:AKTS): The Cautionary Tale That Is Not Even Biotech

Akoustis Technologies is included here so it can be corrected. It is not a biotech or health-technology company. It designs and makes radio-frequency filters using bulk acoustic wave technology for wireless and defense applications, electronics, not medicine.

More importantly, Akoustis is a distressed situation. On the record, the company filed for Chapter 11 bankruptcy protection in the District of Delaware on 16 December 2024, driven by an approximately $59 million final judgment in trade-secret and patent litigation brought by Qorvo. Its common stock was delisted from the Nasdaq and now trades over the counter under the symbol AKTSQ, the Q flagging bankruptcy. The company sold substantially all of its Assets to Tune Holdings, a SpaceX subsidiary, for about $30.2 million in cash following an April 2025 auction, with the sale closing in mid-May 2025, and it has pursued a wind-down of remaining estate assets.

The lesson is blunt. A delisted, liquidating shell is the opposite of the well-funded newcomers above. Investors chasing a familiar ticker should confirm exactly what, and where, they are buying.

What Investors Should Watch

The single most useful habit this basket rewards is verification. Two of these five tickers describe companies that are barely, or not at all, what a casual search might assume: Akoustis Technologies is a bankrupt RF-chip maker, not a biotech, and Conexeu Sciences is a preclinical device story rather than a drug developer.

For the three larger biotechs, the calendar does the work. Eikon's melanoma data, Hemab's move into Phase 3, and Parabilis's planned 2027 Phase 3 start are the catalysts that matter; each is a binary that can reprice the stock sharply in either direction. Cash runway is the second lens; none of these companies earns revenue, so watch quarterly burn against trial timelines.

For Conexeu Sciences, the questions are more basic: liquidity, financing and whether the early-2027 510(k) submission materializes. For Akoustis Technologies, there is nothing left to watch but the bankruptcy docket.

One Listing Guarantees Nothing About the Business Behind It

Four of these five tickers genuinely do sit in the biotech and health-technology spotlight, and they capture 2026's reopened financing window: Eikon, Hemab and Parabilis raised real money at enthusiastic valuations, and Conexeu squeezed onto the small-cap tier with a regenerative pitch. That is the good news, and it is factual. Debut enthusiasm is not durable value, though. Every therapeutics name here lives or dies on clinical readouts that have not yet occurred, and the device story hinges on a regulatory filing still months away. The fifth ticker, Akoustis, is the discipline check: a delisted, bankrupt semiconductor company that belongs in this basket only as a warning about separating the story from the stock.